RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Societal costs and efficiency of subcutaneous versus intravenous lecanemab in early Alzheimer’s disease
A U.S. cost comparison model
Tahami Monfared, A. A., Barrows, S., Fox, L., Herbel, B., Herring, W. L., Krumbach, A., & Zhang, Q. (2025). Societal costs and efficiency of subcutaneous versus intravenous lecanemab in early Alzheimer’s disease: A U.S. cost comparison model. Neurology and Therapy. Advance online publication. https://doi.org/10.1007/s40120-025-00790-2
IntroductionIntravenous (IV) therapies often impose significant burdens and costs on payers, providers, patients, and caregivers. A fixed-dose subcutaneous (SC) formulation may enhance convenience, improve outcomes, and reduce societal costs compared with weight-based IV dosing. This study estimated the relative societal value and cost implications of IV versus SC lecanemab administration for early Alzheimer's disease (AD) in the USA.MethodsA targeted literature review identified outcomes related to IV and SC modes of administration across therapeutic areas to inform and parameterize a cost-comparison model. The model incorporated direct treatment costs; economic value of administration time for providers, patients, and caregivers; and quality-of-life (QOL) impacts for patients and caregivers. Costs were estimated from a societal perspective over 4 years, including a per-patient head-to-head analysis and a population-level assessment accounting for population size, current treatment rates, and SC uptake. Scenario analyses evaluated the impact of key inputs and assumptions on study findings.ResultsSC lecanemab was estimated to yield per-patient savings of $72,891-$80,925 over 4 years compared with IV administration, corresponding to annual savings of $18,223-$20,231 at willingness-to-pay thresholds of $150,000 and $200,000 per quality-adjusted life-year gained, respectively. Savings stemmed from a $40,638 reduction in treatment costs, $8151 decrease in administration time costs, and $24,102-$32,136 reduction in QOL-related costs. At the population level, assuming current treatment rates and 49.4% SC uptake, total savings of $3.16-$3.71 billion were projected over 4 years. Sensitivity analyses indicated per-patient savings varied based on site of care, IV drug wastage, and caregiver disutilities, while population-level savings were sensitive to treatment rates and SC uptake.ConclusionSubcutaneous lecanemab administration potentially offers substantial societal savings by lowering treatment costs, minimizing time demands, and relieving QOL burdens for patients and caregivers. These findings underscore the potential value of SC formulations in improving treatment delivery and alleviating AD economic impact; however, real-world data in AD are needed to further contextualize this comparison.
RTI shares its evidence-based research - through peer-reviewed publications and media - to ensure that it is accessible for others to build on, in line with our mission and scientific standards.